Vaccines

COVID-19 Vaccines COVID-19 Vaccine Development MMR Vaccine Vaccine Safety Respiratory Syncytial Virus (RSV) Covid Vaccines mRNA Vaccines Covid-19 Vaccines Respiratory Syncytial Virus

Merck Tops Q3 Estimates and Raises Profit Outlook

Stronger sales lift guidance, underscoring Merck's push to protect Keytruda through its subcutaneous QLEX plus strategic licensing deals.

Federal Hold on Vaccines for Children Leaves Half of U.S. Kids Without Updated COVID Shots

Pfizer Beats Q1 Forecasts as Newer Drugs Offset COVID Slide

OPS Opens Regional Procurement to Argentine Drugmakers With First Major Vaccine Deal

Brazil’s Single-Dose Dengue Vaccine Shows 5-Year Protection as Rollout to Health Workers Begins

Moderna Reaches Up to $2.25 Billion LNP Patent Settlement, Pays $950 Million Upfront

Autism Researchers Launch Independent Panel to Counter RFK Jr.’s Overhauled Federal Committee

Basque Health Service Probe Finds Systemic Vaccine Lapses, 151 Children Affected

WHO Sets 2026 Flu Vaccine Strains for Northern Hemisphere After H3N2 Variant Gains Ground

U.S. Confidence in MMR, Flu and Covid Vaccines Slips, Survey Finds

CSL Profit Slides on Plasma Weakness as Buyback Hits $750 Million, Interim CEO Appointed

Merck Lifts Mid-2030s Revenue Goal to $70 Billion From Emerging Businesses

Dupixent Powers Sanofi’s Q3 as Vaccine Sales Slip

Merck Wins FDA Approval for Subcutaneous Keytruda as EU Panel Backs Infant RSV Preventive

Health Officials Rebuke Trump’s MMR Claims as UK Pharmacies Report Hesitancy

Greene Urges DOJ to Drop Charges Against Surgeon on Trial for COVID-19 Vaccine Fraud

UK Health Agency Warns of Measles Surge Ahead of Glastonbury

Federal Investigation Examines Claims of Pfizer Vaccine Announcement Delay in 2020

Pfizer Reports Strong Q4 Earnings But Faces Uncertain Market Sentiment

Pfizer Exceeds Q4 Earnings Expectations with Strong Covid Product Sales and Cost Cuts